Alligator Bioscience 和 Aptevo Therapeutics 报告了 ALG 1 期试验的积极中期结果。APV-527 在一项针对各种实体瘤的多中心研究中。 Alligator Bioscience and Aptevo Therapeutics report positive interim results for Phase 1 trial of ALG.APV-527 in a multicenter study for various solid tumors.
Alligator Bioscience 和 Aptevo Therapeutics 报告了其 ALG 1 期试验的积极中期结果。APV-527 是一种靶向 4-1BB 和 5T4 的双特异性抗体，将在 2024 年 ESMO 年会上展示。 Alligator Bioscience and Aptevo Therapeutics reported positive interim results from their Phase 1 trial of ALG.APV-527, a bispecific antibody targeting 4-1BB and 5T4, which will be presented at the ESMO Congress 2024. 多中心试验评估了该药物在患有各种固态肿瘤的成年病人中的安全性、可耐性和初步抗扰效。 The multi-center trial evaluates the drug's safety, tolerability, and preliminary anti-tumor efficacy in adult patients with various solid tumors. ALG.APV-527每两周静脉注射一次。 ALG.APV-527 is administered intravenously every two weeks.